JP2021036883A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021036883A5 JP2021036883A5 JP2020186004A JP2020186004A JP2021036883A5 JP 2021036883 A5 JP2021036883 A5 JP 2021036883A5 JP 2020186004 A JP2020186004 A JP 2020186004A JP 2020186004 A JP2020186004 A JP 2020186004A JP 2021036883 A5 JP2021036883 A5 JP 2021036883A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- nucleic acid
- cells
- domain
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 230000001086 cytosolic effect Effects 0.000 claims 3
- 210000002865 immune cell Anatomy 0.000 claims 3
- 102000002467 interleukin receptors Human genes 0.000 claims 3
- 108010093036 interleukin receptors Proteins 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims 2
- 102000004527 Interleukin-21 Receptors Human genes 0.000 claims 2
- 108010017411 Interleukin-21 Receptors Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 101001004391 Drosophila melanogaster Protein jim lovell Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 230000005809 anti-tumor immunity Effects 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 102000027411 intracellular receptors Human genes 0.000 claims 1
- 108091008582 intracellular receptors Proteins 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 108091006106 transcriptional activators Proteins 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562115527P | 2015-02-12 | 2015-02-12 | |
| US62/115,527 | 2015-02-12 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541919A Division JP6846352B2 (ja) | 2015-02-12 | 2016-02-11 | キメラ抗原受容体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021036883A JP2021036883A (ja) | 2021-03-11 |
| JP2021036883A5 true JP2021036883A5 (https=) | 2021-10-28 |
Family
ID=56614021
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541919A Active JP6846352B2 (ja) | 2015-02-12 | 2016-02-11 | キメラ抗原受容体 |
| JP2020186004A Pending JP2021036883A (ja) | 2015-02-12 | 2020-11-06 | キメラ抗原受容体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017541919A Active JP6846352B2 (ja) | 2015-02-12 | 2016-02-11 | キメラ抗原受容体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10336810B2 (https=) |
| EP (1) | EP3256496B1 (https=) |
| JP (2) | JP6846352B2 (https=) |
| KR (1) | KR102607152B1 (https=) |
| CA (1) | CA2974998C (https=) |
| ES (1) | ES2857998T3 (https=) |
| WO (1) | WO2016127257A1 (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016127257A1 (en) | 2015-02-12 | 2016-08-18 | University Health Network | Chimeric antigen receptors |
| PL3298033T5 (pl) | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
| GB201518816D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| JP7178906B2 (ja) * | 2016-05-19 | 2022-11-28 | ザ ジェネラル ホスピタル コーポレイション | ナチュラルキラー細胞および制御性Ｔ細胞の活性を強化するためのプラットフォームである、その受容体ＩＬ－２Ｒβに繋ぎ止められたインターロイキン－２ |
| CA3032498A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| KR102546839B1 (ko) | 2016-08-03 | 2023-06-23 | 워싱턴 유니버시티 | 키메라 항원 수용체를 이용한 t 세포 악성종양의 치료를 위한 car-t 세포의 유전자 편집 |
| US20190119636A1 (en) | 2017-10-23 | 2019-04-25 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
| WO2018067993A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| JP7291396B2 (ja) | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| CN110191955B (zh) * | 2016-12-13 | 2024-05-31 | 西雅图儿童医院（Dba西雅图儿童研究所） | 在体外和体内对工程化的细胞中表达的化学物质诱导的信号传导复合物进行外源性药物激活的方法 |
| CN111819192A (zh) * | 2018-03-02 | 2020-10-23 | 艾洛基治疗公司 | 可诱导的嵌合细胞激素受体 |
| WO2019175328A1 (en) | 2018-03-14 | 2019-09-19 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Bh4pathwayactivationandusethereoffortreatingcancer |
| WO2019210057A1 (en) | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Rapamycin resistant cells |
| MX2020011254A (es) * | 2018-04-27 | 2020-11-12 | Crispr Therapeutics Ag | Celulas t car anti-bcma para agotamiento de celulas de plasma. |
| CN110615843B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含第三信号受体的嵌合抗原受体及其应用 |
| GB201814203D0 (en) * | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
| CN113272318A (zh) * | 2018-09-05 | 2021-08-17 | 孔锡卿 | 用于实体癌的嵌合抗原受体和表达嵌合抗原受体的t细胞 |
| JP7812549B2 (ja) * | 2019-02-21 | 2026-02-10 | アーベル リミテッド | 人工免疫監視キメラ抗原受容体（ａｉ－ｃａｒ）及びそれを発現する細胞 |
| PE20211902A1 (es) | 2019-03-01 | 2021-09-27 | Allogene Therapeutics Inc | Receptores de citocinas quimericos constitutivamente activos |
| AU2020232216B2 (en) | 2019-03-01 | 2025-09-25 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a PD-1 ectodomain |
| GB201911187D0 (en) * | 2019-08-05 | 2019-09-18 | Autolus Ltd | Receptor |
| GB201912515D0 (en) * | 2019-08-30 | 2019-10-16 | King S College London | Engineered regulatory T cell |
| US12528856B2 (en) | 2019-08-30 | 2026-01-20 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors comprising TGF β binding domains |
| US20220372105A1 (en) * | 2019-09-05 | 2022-11-24 | Poseida Therapeutics, Inc. | Allogeneic cell compositions and methods of use |
| CN110717956B (zh) * | 2019-09-30 | 2023-06-20 | 重庆大学 | 一种有限角投影超像素引导的l0范数最优化重建方法 |
| TWI717880B (zh) | 2019-10-24 | 2021-02-01 | 中國醫藥大學附設醫院 | Hla-g特異性嵌合抗原受體、核酸、hla-g特異性嵌合抗原受體表達質體、表達hla-g特異性嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物 |
| AU2021208559A1 (en) * | 2020-01-14 | 2022-07-07 | Synthekine, Inc. | CD122 with altered ICD STAT signaling |
| KR20220141299A (ko) * | 2020-01-14 | 2022-10-19 | 신테카인, 인크. | Il2 오르토로그 및 사용 방법 |
| MX2022010340A (es) | 2020-02-24 | 2022-09-19 | Allogene Therapeutics Inc | Celulas t con car de bcma con actividades mejoradas. |
| CN115427440A (zh) * | 2020-02-25 | 2022-12-02 | 圭尔医疗有限公司 | 用于工程化细胞的嵌合受体 |
| WO2021183795A1 (en) * | 2020-03-11 | 2021-09-16 | Poseida Therapeutics, Inc. | Chimeric stimulatory receptors and methods of use in t cell activation and differentiation |
| AU2021256473A1 (en) * | 2020-04-17 | 2022-12-22 | The Council Of The Queensland Institute Of Medical Research | Immune cells with enhanced function |
| EP4139345A1 (en) * | 2020-04-24 | 2023-03-01 | Sorrento Therapeutics, Inc. | Memory dimeric antigen receptors |
| KR102297396B1 (ko) | 2020-07-29 | 2021-09-06 | (주)티카로스 | 면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포 |
| US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
| KR20220082775A (ko) | 2020-12-10 | 2022-06-17 | 주식회사 유틸렉스 | 항-pd-1 항체 및 이의 용도 |
| CN114716548B (zh) | 2021-01-05 | 2024-11-05 | (株)爱恩德生物 | 抗-fgfr3抗体及其用途 |
| CN113512125B (zh) * | 2021-04-26 | 2024-01-19 | 北京双赢科创生物科技有限公司 | 一种携带stat结合基序的嵌合抗原受体分子及表达该嵌合抗原受体分子的nk细胞 |
| AU2022348588A1 (en) | 2021-09-17 | 2024-04-04 | Parker Institute For Cancer Immunotherapy | Switch receptors using il-9 signaling domains |
| WO2023158997A2 (en) * | 2022-02-15 | 2023-08-24 | Memorial Sloan-Kettering Cancer Center | Compositions including killer innate-like t cells and uses therof |
| US20250154463A1 (en) * | 2022-02-15 | 2025-05-15 | Memorial Sloan-Kettering Cancer Center | Compositions including cytotoxic innate lymphoid cells and uses thereof |
| EP4554972A1 (en) * | 2022-07-11 | 2025-05-21 | The Board of Trustees of the Leland Stanford Junior University | Tunable cytokine receptor signaling domains |
| KR20240016216A (ko) | 2022-07-26 | 2024-02-06 | (주)에임드바이오 | 항-ror1 항체 및 이의 용도 |
| EP4342907A1 (en) | 2022-09-21 | 2024-03-27 | AvenCell Europe GmbH | Switchable chimeric antigen receptors and their use |
| AU2023353989A1 (en) | 2022-09-30 | 2025-02-27 | Caribou Biosciences, Inc. | Anti-ror1 chimeric antigen receptors (cars), cells expressing the cars and related methods |
| WO2024129964A1 (en) * | 2022-12-15 | 2024-06-20 | Carisma Therapeutics Inc. | Chimeric antigen receptors including jak/stat binding domains and modified immune cells |
| WO2025096673A1 (en) * | 2023-10-30 | 2025-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions comprising cells targeting cancer and methods of using the same |
| WO2026006794A1 (en) * | 2024-06-27 | 2026-01-02 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric antigen receptors and uses thereof |
| WO2026024468A1 (en) | 2024-07-26 | 2026-01-29 | Caribou Biosciences, Inc. | Modular linked chimeric antigen receptors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| US5837544A (en) * | 1995-02-02 | 1998-11-17 | Cell Genesys, Inc. | Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase |
| US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| EP1795599A1 (en) | 2005-12-09 | 2007-06-13 | Schuler, Gerold, Prof. Dr. | Methods for generating antigen-specific effector T cells |
| US8119772B2 (en) | 2006-09-29 | 2012-02-21 | California Institute Of Technology | MART-1 T cell receptors |
| WO2010089412A1 (en) | 2009-02-09 | 2010-08-12 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof |
| WO2012154858A1 (en) | 2011-05-09 | 2012-11-15 | Whitehead Institute For Biomedical Research | Chaperone interaction assays and uses thereof |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| EP3783098A1 (en) | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| CA2913052A1 (en) * | 2013-05-24 | 2014-11-27 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| WO2016127257A1 (en) | 2015-02-12 | 2016-08-18 | University Health Network | Chimeric antigen receptors |
-
2016
- 2016-02-11 WO PCT/CA2016/050126 patent/WO2016127257A1/en not_active Ceased
- 2016-02-11 CA CA2974998A patent/CA2974998C/en active Active
- 2016-02-11 ES ES16748518T patent/ES2857998T3/es active Active
- 2016-02-11 KR KR1020177025120A patent/KR102607152B1/ko active Active
- 2016-02-11 JP JP2017541919A patent/JP6846352B2/ja active Active
- 2016-02-11 US US15/550,645 patent/US10336810B2/en active Active
- 2016-02-11 EP EP16748518.4A patent/EP3256496B1/en active Active
-
2019
- 2019-05-14 US US16/411,941 patent/US10822392B2/en active Active
-
2020
- 2020-11-06 JP JP2020186004A patent/JP2021036883A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021036883A5 (https=) | ||
| JP2024138280A5 (https=) | ||
| Morgan et al. | High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens | |
| JP7198670B2 (ja) | 免疫調整性ｉｌ２ｒ融合タンパク質およびその使用 | |
| JP2022109953A5 (https=) | ||
| JP2021536249A5 (https=) | ||
| TW202000691A (zh) | 嵌合跨膜蛋白及其用途 | |
| JP2018523484A5 (https=) | ||
| JP2021500894A (ja) | キメラ抗原受容体発現細胞を作製する方法 | |
| JP2019517267A5 (https=) | ||
| JP2021536240A (ja) | 改良された治療用ｔ細胞 | |
| CN114391021B (zh) | TGF-β受体和使用方法 | |
| CN112771167A (zh) | 表达有趋化因子的细胞及用途 | |
| JP2019513394A5 (https=) | ||
| Tal et al. | An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities | |
| JP7466231B2 (ja) | キメラ抗原受容体及びその適用 | |
| Rubinstein et al. | Transfer of TCR genes into mature T cells is accompanied by the maintenance of parental T cell avidity | |
| JP2021516049A (ja) | 組換えｔ細胞受容体遺伝子を用いて細胞ベースの治療薬を製造するための技法 | |
| CN111875712A (zh) | 一种增强型靶向muc1的嵌合抗原受体及其应用 | |
| WO2025031441A1 (en) | Engineered cells expressing trimeric complexes | |
| JP2015223143A (ja) | Ｔｃｒの細胞傷害活性誘導能を評価するためのｎｋ細胞株、およびその作製方法 | |
| CN121969385A (zh) | 含有il-2变体以增强car t细胞的功能性的car-衔接子 | |
| TWI790162B (zh) | 新穎t細胞受器及使用其之免疫治療 | |
| US12606608B2 (en) | Modified NK-92 cells, and therapeutic and diagnostic uses thereof | |
| CN115820697B (zh) | 一种免疫细胞及其制备方法和应用 |